8-K: Lifecore Biomedical Announces Change in Independent Auditor as Ernst & Young Declines Reappointment

Lifecore Biomedical has announced that Ernst & Young will not stand for reappointment as their independent auditor, prompting a search for a new firm.

Summary

• Lifecore Biomedical received notice on March 20, 2024, that Ernst & Young LLP declined to be reappointed as their independent auditor for the fiscal year ending May 26, 2024.
• Ernst & Young's audit report for the fiscal year ended May 28, 2023, did not contain any adverse opinions, disclaimers, or qualifications.
• The audit report for the fiscal year ended May 29, 2022, included an explanatory paragraph about the company's ability to continue as a going concern, but no adverse opinions or qualifications.
• There were no disagreements between Lifecore and Ernst & Young regarding accounting principles, financial disclosures, or auditing procedures during the fiscal years ended May 28, 2023, and May 29, 2022, and the subsequent interim period.
• Ernst & Young did issue an adverse opinion on internal control over financial reporting for both fiscal years due to material weaknesses, which Lifecore had previously reported.
• Lifecore has begun discussions with other accounting firms to find a new independent auditor and will disclose the engagement as required by SEC regulations.

Sentiment

Score: 3

Explanation: The document contains negative news regarding the change of auditors and material weaknesses in internal controls, which is likely to negatively impact investor confidence.

Positives

• Ernst & Young's audit report for the fiscal year ended May 28, 2023, did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles.
• There were no disagreements between Lifecore and Ernst & Young on any matters of accounting principles or practices, financial statement disclosure, or auditing scope and procedures.

Negatives

• Ernst & Young declined to be reappointed as Lifecore's independent auditor.
• Ernst & Young issued adverse opinions on internal control over financial reporting for both fiscal years 2023 and 2022 due to material weaknesses.

Risks

• The change in auditors could create uncertainty for investors.
• The material weaknesses in internal control over financial reporting, as highlighted by Ernst & Young, pose a risk to the accuracy of financial statements.
• The company's ability to continue as a going concern was previously questioned by Ernst & Young in 2022.

Future Outlook

Lifecore will engage a new independent registered public accounting firm and disclose the engagement as required by SEC rules and regulations.

Industry Context

Changes in auditors are not uncommon, but the circumstances surrounding this change, including the adverse opinion on internal controls, may raise concerns among investors and industry analysts.

Comparison to Industry Standards

• The change in auditors is not unusual, but the reason for the change, with Ernst & Young declining reappointment, is less common and may raise concerns.
• The adverse opinion on internal controls is a significant issue, as it indicates potential weaknesses in the company's financial reporting processes. This is not in line with best practices for public companies.
• Companies with strong internal controls typically receive clean opinions from their auditors, and the material weaknesses identified by Ernst & Young are a cause for concern.

Stakeholder Impact

• Shareholders may be concerned about the change in auditors and the identified material weaknesses in internal controls.
• Employees may experience uncertainty due to the change in auditors and potential implications for financial reporting processes.
• Creditors may be concerned about the company's financial reporting and internal controls.

Next Steps

• Lifecore will engage a new independent registered public accounting firm.
• Lifecore will disclose the engagement of the new auditor as required by SEC regulations.

Key Dates

Keywords

auditor, Ernst & Young, independent accounting firm, financial reporting, internal control, material weakness, audit, SEC, Lifecore Biomedical